Published in Thorax on December 01, 2001
Importance of cytokines in murine allergic airway disease and human asthma. J Immunol (2010) 1.86
Serum interleukin-5 levels are elevated in mild and moderate persistent asthma irrespective of regular inhaled glucocorticoid therapy. BMC Pulm Med (2004) 0.88
IL-5 in asthma. Thorax (2002) 0.75
Duplicate publication. Am J Respir Crit Care Med (2002) 0.75
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med (1992) 11.90
Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med (1996) 6.34
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 3.82
Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med (1995) 2.83
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med (1997) 2.77
Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med (1997) 2.77
The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med (2000) 2.07
Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest (1997) 1.86
Role of mast cells, eosinophils and IL-5 in the development of airway hyperresponsiveness in sensitized mice. Clin Exp Allergy (1996) 1.62
Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med (1999) 1.47
Effect of methacholine challenge on cellular composition of sputum induction. Thorax (1999) 1.45
CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am Rev Respir Dis (1993) 1.43
Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med (1995) 1.40
Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med (1997) 1.39
Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med (1998) 1.37
The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity. J Immunol (2000) 1.20
Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest (1998) 1.18
Effect of repeated sputum induction on cell counts in normal volunteers. Thorax (1998) 1.18
An essential role for interleukin-5 and eosinophils in helminth-induced airway hyperresponsiveness. Infect Immun (1998) 1.12
TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. Am J Respir Crit Care Med (1999) 1.11
Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony-stimulating factor, and IL-3. Am J Respir Cell Mol Biol (1997) 1.10
IL-5 and IL-5 receptor in asthma. Mem Inst Oswaldo Cruz (1997) 1.04
Kinetics of allergen-induced airway eosinophilic cytokine production and airway inflammation. Am J Respir Crit Care Med (1999) 1.02
Activated eosinophils are the major source of Th2-associated cytokines in the schistosome granuloma. J Immunol (1999) 1.01
Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung (1999) 0.97
Effect of murine recombinant interleukin-5 on the cell population in guinea-pig airways. Br J Pharmacol (1992) 0.94
Cellular and molecular mechanisms involved in the regulation of eosinophil trafficking in vivo. Med Res Rev (1996) 0.91
alpha4 integrin-dependent eotaxin induction of bronchial hyperresponsiveness and eosinophil migration in interleukin-5 transgenic mice. Am J Respir Cell Mol Biol (1999) 0.89
Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma. Thorax (1994) 0.87
Evaluation of airway hyperreactivity in interleukin-5 transgenic mice. Int Arch Allergy Immunol (1995) 0.85
[Report on the first nationwide survey of the distribution of human parasites in China. 1. Regional distribution of parasite species]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (1994) 0.85
Effect of inhaled interleukin-5 on number and activity of eosinophils in circulation from asthmatics. Clin Immunol (1999) 0.83
Bone marrow progenitors in allergic airways diseases: studies in canine and human models. Int Arch Allergy Immunol (1997) 0.83
The role of interleukin-5 (IL-5) in allergic airway hyperresponsiveness in mice. Ann N Y Acad Sci (1996) 0.82
Regulation of IL-5 and IL-5 receptor expression in the bone marrow of allergic asthmatics. Int Arch Allergy Immunol (1999) 0.81
Eosinophil chemoattractants generated in vivo. Agents Actions Suppl (1995) 0.81
Rapid and selective induction of blood eosinophilia in guinea pigs by recombinant human interleukin 5. Cytokine (1995) 0.80
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med (2000) 9.44
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med (1996) 5.53
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med (2001) 5.47
Increased nitric oxide in exhaled air of asthmatic patients. Lancet (1994) 5.39
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J (2005) 5.24
Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) (1998) 4.31
Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet (2001) 3.48
Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med (1999) 3.44
Asthma as an axon reflex. Lancet (1986) 3.26
Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med (1999) 3.22
Single-dose slow-release aminophylline at night prevents nocturnal asthma. Lancet (1982) 3.21
A new perspective on concepts of asthma severity and control. Eur Respir J (2008) 3.16
Exhaled markers of pulmonary disease. Am J Respir Crit Care Med (2001) 3.14
Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol (2000) 3.13
Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J (2005) 3.05
Neural control of human airways in health and disease. Am Rev Respir Dis (1986) 2.97
The diagnosis and management of chronic cough. Eur Respir J (2004) 2.96
Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J (1997) 2.79
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med (1997) 2.77
Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax (1998) 2.71
A community study of sleep-disordered breathing in middle-aged Chinese men in Hong Kong. Chest (2001) 2.66
Exacerbations of chronic obstructive pulmonary disease. Eur Respir J (2007) 2.65
Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis (1987) 2.64
Cytokines in asthma. Thorax (1999) 2.64
[Hyperventilation: not a cause of panic attacks]. Ned Tijdschr Geneeskd (1993) 2.64
Inflammatory mediators of asthma: an update. Pharmacol Rev (1998) 2.54
Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med (1992) 2.52
Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet (1986) 2.41
ERS guidelines on the assessment of cough. Eur Respir J (2007) 2.36
Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough. Thorax (2004) 2.36
Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med (2000) 2.33
Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med (1992) 2.32
Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med (1996) 2.32
Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med (1995) 2.28
Difficult asthma. BMJ (1989) 2.28
Circulating catecholamines in exercise and hyperventilation induced asthma. Thorax (1981) 2.22
Exhaled carbon monoxide in childhood asthma. J Pediatr (1999) 2.19
Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med (1998) 2.19
Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J (2001) 2.18
Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J (2004) 2.18
Inflammatory mediators and asthma. Pharmacol Rev (1988) 2.17
Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J (2007) 2.16
STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J (2004) 2.06
Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J (1996) 2.05
Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J (2002) 2.04
Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med (2000) 2.03
Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax (2005) 1.99
The effect of airway epithelium on smooth muscle contractility in bovine trachea. Br J Pharmacol (1985) 1.98
Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun (2004) 1.98
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med (1999) 1.96
Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun (1994) 1.96
Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J (2004) 1.95
Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.94
Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med (1999) 1.92
Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med (1997) 1.91
A calcium antagonist, nifedipine, modifies exercise-induced asthma. Thorax (1981) 1.90
Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis (1985) 1.89
T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol (2009) 1.89
Coughing frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder. Eur Respir J (1994) 1.89
Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med (2001) 1.88
Sputum induction. Eur Respir J Suppl (2002) 1.88
Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med (2007) 1.86
Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med (1995) 1.84
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy (2004) 1.84
A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med (1997) 1.84
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J (1995) 1.80
Regulation of human lung epithelial cell numbers by diesel exhaust particles. Eur Respir J (2006) 1.79
Brittle asthma. Thorax (1998) 1.77
Importance of inhaler devices in the management of airway disease. Respir Med (2007) 1.76
Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin Exp Allergy (1997) 1.76
Airway inflammation after controlled exposure to diesel exhaust particulates. Am J Respir Crit Care Med (2000) 1.75
Circulating catecholamines in acute asthma. Br Med J (Clin Res Ed) (1985) 1.73
Is immunotherapy for asthma worthwhile? N Engl J Med (1996) 1.72
Standardised methodology of sputum induction and processing. Eur Respir J Suppl (2002) 1.70
Frequent exacerbators--a distinct phenotype of severe asthma. Clin Exp Allergy (2014) 1.69
Effect of inhaled corticosteroids on bones and growth. Eur Respir J (1998) 1.68
Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax (2004) 1.68
Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J (2003) 1.68
Role of inflammation in the hyperreactivity of the airways in asthma. Thorax (1986) 1.68
Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med (1995) 1.67
Pseudo-steroid resistant asthma. Thorax (1999) 1.67